Amy Schaberg

865 total citations
26 papers, 703 citations indexed

About

Amy Schaberg is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Amy Schaberg has authored 26 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 2 papers in Surgery. Recurrent topics in Amy Schaberg's work include Inhalation and Respiratory Drug Delivery (9 papers), Cystic Fibrosis Research Advances (8 papers) and Neonatal Respiratory Health Research (6 papers). Amy Schaberg is often cited by papers focused on Inhalation and Respiratory Drug Delivery (9 papers), Cystic Fibrosis Research Advances (8 papers) and Neonatal Respiratory Health Research (6 papers). Amy Schaberg collaborates with scholars based in United States, Canada and Australia. Amy Schaberg's co-authors include Donald J. Kellerman, Lisa M. LaVange, Frank J. Accurso, Todd A. Durham, David S. Pearlman, Richard B. Moss, William F. Schoenwetter, Kelly K. Nichols, Benjamin R. Yerxa and Joseph Tauber and has published in prestigious journals such as Circulation, Gastroenterology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Amy Schaberg

26 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Schaberg United States 11 457 324 112 95 62 26 703
Claudia R. Morris United States 5 130 0.3× 217 0.7× 17 0.2× 10 0.1× 66 1.1× 9 402
Giulio Ruberto Italy 11 101 0.2× 46 0.1× 32 0.3× 2 0.0× 70 1.1× 27 399
Dean Quinn New Zealand 11 273 0.6× 403 1.2× 9 0.1× 8 0.1× 154 2.5× 20 789
Paul Stoll Germany 12 268 0.6× 193 0.6× 13 0.1× 78 0.8× 84 1.4× 28 521
Susan Potts United States 14 104 0.2× 88 0.3× 61 0.5× 18 0.3× 24 451
V SWYSTUN Canada 8 729 1.6× 993 3.1× 22 0.2× 4 0.0× 97 1.6× 10 1.1k
Caroline Scott United Kingdom 14 19 0.0× 194 0.6× 74 0.7× 4 0.0× 395 6.4× 19 717
Krishna Yanamandra United States 13 128 0.3× 48 0.1× 47 0.4× 1 0.0× 42 0.7× 18 348
Joyce L. deJong United States 10 51 0.1× 19 0.1× 32 0.3× 4 0.0× 90 1.5× 38 436
T. Radeau France 10 34 0.1× 82 0.3× 94 0.8× 60 1.0× 14 355

Countries citing papers authored by Amy Schaberg

Since Specialization
Citations

This map shows the geographic impact of Amy Schaberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Schaberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Schaberg more than expected).

Fields of papers citing papers by Amy Schaberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Schaberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Schaberg. The network helps show where Amy Schaberg may publish in the future.

Co-authorship network of co-authors of Amy Schaberg

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Schaberg. A scholar is included among the top collaborators of Amy Schaberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Schaberg. Amy Schaberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ratjen, Félix, Todd A. Durham, Tomáš Navrátil, et al.. (2012). Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis. 11(6). 539–549. 67 indexed citations
2.
Accurso, Frank J., et al.. (2010). Potential of denufosol as an early intervention in CF lung disease: efficacy in patients with minimal pharmacotherapy in a US phase 3 clinical trial. Journal of Cystic Fibrosis. 9. S21–S21. 2 indexed citations
3.
Accurso, Frank J., Richard B. Moss, Robert W. Wilmott, et al.. (2010). Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. American Journal of Respiratory and Critical Care Medicine. 183(5). 627–634. 63 indexed citations
4.
Navrátil, Tomáš, C D Evans, Amy Schaberg, et al.. (2010). Aerosol and pharmacokinetic properties of denufosol support its use for early intervention in CF lung disease. Journal of Cystic Fibrosis. 9. S21–S21. 1 indexed citations
5.
Navrátil, Tomáš, Amy Schaberg, Wei Tian, et al.. (2010). Potential of Denufosol as an Early Intervention Therapy for CF Lung Disease. The FASEB Journal. 24(S1). 1 indexed citations
6.
7.
8.
Mospan, Andrea R., Todd A. Durham, Amy Schaberg, & Frank J. Accurso. (2009). Effects of denufosol on sinusitis-related complaints in a phase 3 trial in cystic fibrosis patients. Journal of Cystic Fibrosis. 8. S26–S26. 1 indexed citations
9.
Accurso, Frank J., Todd A. Durham, & Amy Schaberg. (2009). Relationship between pulmonary exacerbations and lung function decline in a six month trial of denufosol. Journal of Cystic Fibrosis. 8. S26–S26. 1 indexed citations
10.
Kellerman, Donald J., et al.. (2008). Denufosol: A review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulmonary Pharmacology & Therapeutics. 21(4). 600–607. 73 indexed citations
11.
Moss, Richard B., Alison Heald, Dana Mathews, et al.. (2005). 97 INS37217 (denufosol tetrasodium) inhalation solution: Phase 1 & 2 clinical experience. Journal of Cystic Fibrosis. 4. S27–S27. 1 indexed citations
12.
Moss, Richard B., Alison Heald, Dana Mathews, et al.. (2005). 98 Safety and Efficacy of INS37217 Inhalation Solution in Patient Subgroups: Results of a Phase 2 Multicentre Trial. Journal of Cystic Fibrosis. 4. S27–S27. 1 indexed citations
13.
Deterding, Robin R., George Retsch‐Bogart, Laura Milgram, et al.. (2005). Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatric Pulmonology. 39(4). 339–348. 74 indexed citations
14.
Tauber, Joseph, William F. Davitt, Kelly K. Nichols, et al.. (2004). Double-Masked, Placebo-Controlled Safety and Efficacy Trial of Diquafosol Tetrasodium (INS365) Ophthalmic Solution for the Treatment of Dry Eye. Cornea. 23(8). 784–792. 130 indexed citations
15.
Barber, Laurie, Todd A. Durham, Lisa M. LaVange, et al.. (2004). Effect of Diquafosol On Worst Symptom of Dry Eye Patients: Focus on Photophobia. 45(13). 3914–3914. 1 indexed citations
16.
Schaberg, Amy, E.O. Meltzer, Craig LaForce, et al.. (2003). INS37217 intranasal, a P2Y2 receptor agonist, is a novel treatment for allergic rhinitis. Journal of Allergy and Clinical Immunology. 111(2). S74–S74. 1 indexed citations
17.
Mahajan, Puneet, et al.. (1997). Impact of Fluticasone Propionate Powder on Health-Related Quality of Life in Patients with Moderate Asthma. Journal of Asthma. 34(3). 227–234. 44 indexed citations
18.
Pearlman, David S., Michael Noonan, Donald P. Tashkin, et al.. (1997). Comparative Efficacy and Safety of Twice Daily Fluticasone Propionate Powder Versus Placebo in the Treatment of Moderate Asthma. Annals of Allergy Asthma & Immunology. 78(4). 356–362. 48 indexed citations
19.
Wasserman, Stephen I., Gary N. Gross, William F. Schoenwetter, et al.. (1996). A 12-Week Dose-Ranging Study of Fluticasone Propionate Powder in the Treatment of Asthma. Journal of Asthma. 33(4). 265–274. 59 indexed citations
20.
Selner, John C., et al.. (1996). Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clinical Therapeutics. 18(4). 635–646. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia R. Morris Breakdown of academic impact, for papers by Giulio Ruberto Breakdown of academic impact, for papers by Dean Quinn Breakdown of academic impact, for papers by Paul Stoll Breakdown of academic impact, for papers by Susan Potts Breakdown of academic impact, for papers by V SWYSTUN Breakdown of academic impact, for papers by Caroline Scott Breakdown of academic impact, for papers by Krishna Yanamandra Breakdown of academic impact, for papers by Joyce L. deJong Breakdown of academic impact, for papers by T. Radeau
Rankless by CCL
2026